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Abstract
Background: Immune checkpoint inhibitors (ICIs) have changed the clinical management of melanoma. However,
not all patients respond, and current biomarkers including PD-L1 and mutational burden show incomplete
predictive performance. The clinical validity and utility of complex biomarkers have not been studied in melanoma.
Methods: Cutaneous metastatic melanoma patients at eight institutions were evaluated for PD-L1 expression, CD8+
T-cell infiltration pattern, mutational burden, and 394 immune transcript expression. PD-L1 IHC and mutational
burden were assessed for association with overall survival (OS) in 94 patients treated prior to ICI approval by the
FDA (historical-controls), and in 137 patients treated with ICIs. Unsupervised analysis revealed distinct immune-
clusters with separate response rates. This comprehensive immune profiling data were then integrated to generate
a continuous Response Score (RS) based upon response criteria (RECIST v.1.1). RS was developed using a single
institution training cohort (n = 48) and subsequently tested in a separate eight institution validation cohort (n = 29)
to mimic a real-world clinical scenario.
Results: PD-L1 positivity ≥1% correlated with response and OS in ICI-treated patients, but demonstrated limited
predictive performance. High mutational burden was associated with response in ICI-treated patients, but not with
OS. Comprehensive immune profiling using RS demonstrated higher sensitivity (72.2%) compared to PD-L1 IHC
(34.25%) and tumor mutational burden (32.5%), but with similar specificity.
Conclusions: In this study, the response score derived from comprehensive immune profiling in a limited
melanoma cohort showed improved predictive performance as compared to PD-L1 IHC and tumor mutational
burden.
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Background
The introduction of immune checkpoint inhibitors (ICIs)
revolutionized the clinical management of patients with
metastatic melanoma [1–8]. However, only a minority of
patients obtain durable clinical benefit from ICIs. [1, 4, 6–
8] Moreover, ICI-based immunotherapy is associated with
significant immune related side effects [1, 4, 6–8], and it
has an estimated cost of over $300,000 per quality-adjusted
life-year, [9] calling for the development of robust predictive
biomarkers [10]. Despite considerable efforts in this direc-
tion, the identification and validation of biomarkers that
would predict the response of melanoma patients to ICIs
targeting cytotoxic T lymphocyte associated protein 4
(CTLA4) or programmed cell death 1 (PDCD1, best known
as PD-1), has not been very successful so far. In particular,
neither assessing intratumoral expression levels of CD274
(best known as PD-L1) by immunohistochemistry, nor
evaluating tumor mutational burden by whole-exome se-
quencing appears to suffice to predict long-term clinical
benefits [3–8, 10–13]. Moreover, it has become clear that
robust predictions may involve different biomarkers in pa-
tients receiving CTLA- versus PD-1-targeting agents [4,
14]. The results of the CHECKMATE 067 clinical trial
demonstrated that better objective response rates (ORRs)
and overall survival (OS) in PD-L1 negative patients for the
combination of dual agent CTLA-4 and PD-1 targeting
ICIs [14, 15]. Based on these findings, some oncologists are
currently using negative PD-L1 expression to move past
monotherapy and prescribe dual ICIs, while others consider
patient preference and perceived tolerability without bio-
markers to aid clinical decision making, despite the risk of
increased rates of adverse events (AEs) [14]. A global inves-
tigation of the mutational and immunological aspects of
the disease, going beyond the standalone assessment of mu-
tational burden and PD-L1 expression levels, is critical to
the development of superior predictive biomarkers for mel-
anoma patients treated with ICIs.
The genomic landscape of melanoma, performed by The
Cancer Genome Atlas (TCGA) on 333 melanoma samples
delineated 4 genomic subtypes, i.e., triple wild-type (WT),
BRAF mutant, NRAS, HRAS or KRAS mutant, and NF1
mutant, as well as three transcriptomic subclasses, i.e., im-
mune, keratin and MIFT-low. [16] Although this provided
several useful insights into the disease, it did not improve
our ability to predict clinical responses to ICIs amongst
melanoma patients. To address this gap, we performed a
comprehensive analysis of the mutational and immuno-
logical landscape of 300 samples from metastatic melan-
oma patients at eight institutions worldwide using a CLIA/
CAP-certified NYS-approved laboratory developed test
(LDT) [17]. This test evaluates PD-L1 expression levels,
CD8+ T-cell tumor infiltration pattern by immunohisto-
chemistry, mutational burden by whole-exon DNA-seq, as
well as the abundance of 394 immune transcripts by RNA-
seq. [17] Each of these parameters was studied individually
in a dichotomous manner for their influence on ORR and
OS in patients undergoing surgery prior to the approval of
ipilimumab in 2011, i.e. historical controls, versus patients
receiving ICI-based immunotherapy, which allowed for the
differentiation between prognostic and predictive bio-
markers. Finally, a training cohort of 48 ICI-treated pa-
tients was used to develop a continuous response score
(RS), subsequently tested on a validation cohort of an add-
itional 29 ICI-treated patients.
Methods
Patients and clinical data
Eight collaborating institutions obtained approval by their
respective institutional review boards (IRBs) to submit
existing de-identified specimens and associated clinical
data for use in this study (Additional file 1: Table S1). A
total of 300 patients were included in the study, based on
the following criteria: history of metastatic cutaneous mel-
anoma with surgical resection of a primary or metastatic
tumor; availability of adequate archival formalin-fixed
paraffin-embedded (FFPE) tissue collected prior to treat-
ment with ICIs; availability of sequencing data; and avail-
ability of demographic, diagnosis, follow-up and vital status
data. Patients were excluded if they died within three
months of initial diagnosis, or were alive at last follow-up,
but had less than six months of follow-up time from initial
diagnosis of metastatic disease. Based on the initial ap-
proval of ipilimumab by the US FDA (March 25th, 2011),
patients with biopsies demonstrating Stage IV disease prior
to the availability of ICIs (1992–2010) were included as his-
torical controls (n = 94). Medical and electronic pharmacy
records were reviewed to identify individuals receiving
FDA-approved checkpoint inhibitors (n = 166) for which a
subset (n = 137) with a median follow-up of 16.2 months
was used for survival analysis. This latter group of 137 pa-
tients is referred to as the ICI-treated group (Table 1), and
for which 78 of these were evaluable and 59 not evaluable
(Additional file 1: Table S8) for response to treatment by
RECIST v1.1 (Additional file 1: Table S1) [18]. From this
group of 78 patients a total of 77 had complete measure-
ments and were divided into a training set (48 patients)
from a single institution (RPCCC) and a validation set (29
patients) from eight different institutions and were used to
develop a Response Score (RS) for prediction of response
to ICI. The training cohort represented the largest popula-
tion from a single institution, whereas the validation cohort
represented multiple patients from various institutions. A
complete review of all patient dispositions is included in
the Additional file 7 (Additional file 2: Figure S1).
Immunohistochemical studies
The expression of PD-L1 on the surface of tumor cells
was assessed in all samples by means of the Dako Omnis
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Table 1 Clinical characteristics
All Casesa Pre-ipi approval Post-ipi approval Post-ipi approval
(n = 300) (n = 94) (n = 206) (n = 206)
ICI Treated ICI Not Treated
Age at initial cutaneous melanoma diagnosis (Years, %) (n = 160) (n = 46)
< 30 9 (03.0) 5 (05.3) 4 (01.9) 2 (01.3) 2 (04.3)
30–39 25 (08.3) 11 (11.7) 14 (06.8) 9 (05.6) 5 (10.9)
40–49 49 (16.3) 15 (16.0) 34 (16.5) 26 (16.3) 8 (17.4)
50–59 69 (23.0) 25 (26.6) 44 (21.4) 37 (23.1) 7 (15.2)
60–69 68 (22.7) 17 (18.1) 51 (24.8) 40 (25.0) 11 (23.9)
70–79 51 (17.0) 13 (13.8) 38 (18.4) 31 (19.4) 7 (15.2)
≥ 80 29 (09.7) 8 (08.5) 21 (10.2) 15 (09.4) 6 (13.0)
Mean 59 56 60 61 58
Year of diagnosis (Range) 1974–2016 1974–2010 1989–2016 1990–2016 1989–2016
Sex
Female 111 (37.0) 36 (38.3) 75 (36.4) 53 (33.1) 22 (47.8)
Male 189 (63.0) 58 (61.7) 131 (63.6) 107 (66.9) 24 (52.2)
Race
White 293 (97.7) 94 (100.0) 199 (96.6) 154 (96.3) 45 (97.8)
Other 2 (06.0) 0 (00.0) 2 (01.0) 1 (00.6) 1 (02.2)
Unknown 5 (01.7) 0 (00.0) 5 (02.4) 5 (03.1) 0 (00.0)
Vital status at last follow up
Alive 136 (45.3) 16 (17.0) 120 (58.3) 92 (57.5) 28 (60.9)
Dead 164 (54.7) 78 (83.0) 86 (41.7) 68 (42.5) 18 (39.1)
Year of bx proven Stage IV disease (range) 1992–2017 1992–2011 2011–2017 2011–2017 2011–2017
Months of follow up (Median)b 16.2 16.5 16.2 16.2 15.5
< 1 13 (04.3) 0 (00.0) 13 (06.3) 10 (06.3) 3 (06.5)
3 122 (40.7) 0 (00.0) 122 (59.2) 104 (65.0) 18 (39.1)
6 74 (24.7) 3 (03.2) 71 (34.5) 46 (28.8) 25 (54.3)
10 42 (14.0) 42 (44.7) 0 (00.0) 0 (00.0) 0 (00.0)
> 10 49 (16.3) 49 (52.1) 0 (00.0) 0 (00.0) 0 (00.0)
Median 4.4 10 3 2.8 4.2
Years from diagnosis to bx proven Stage IV disease (Median) 1.1 1.5 1 1 0.7
Received BRAF TKI (Yes, %) 25 (08.3) 0 (00.0) 25 (12.1) 19 (11.9) 6 (13.0)
Mo from specimen collection to BRAF TKI (Median) 6·5 N/A 6·5 8 6
Checkpoint inhibitor
Ipilimumab 72 (45.0) N/A
Pembrolizumab 68 (42.5) N/A
Nivolumab 7 (04.4) N/A
Ipilimumab + Nivolumab 13 (08.1) N/A
Time to progression (median days) 77.5 N/A
Progression free survival (median days) 129.5 N/A
aAll cases are metastatic and no cutaneous samples included. bFor pre-ipi approval patients follow-up is the number of months from date of specimen collection
(bx proven Stage IV disease) to last date of follow up or date of death, and for post-ipi approval patients represents the number of months from date of first dose
of checkpoint inhibitor to last date of follow up or date of death
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platform (Agilent, Santa Clara, CA) and the 28–8
pharmDx antibody. Expression levels, and were scored
as per published guidelines [19]. Additional serially sec-
tioned tissue was evaluated for lymphocyte infiltration
using the anti-CD8 antibody C8/144B (Agilent, Santa
Clara, CA) and assigned a qualitative score of non-
infiltrated, infiltrated, or excluded. Non-infiltrated re-
ferred to a sparse number of CD8+ T-cells that infiltrate
nests of neoplastic cells and with less than 5% of the
tumor showing an infiltrating pattern. Infiltrated repre-
sents frequent CD8+ T-cells that infiltrate nests of neo-
plastic cells in an overlapping fashion at least focally and
in more than 5% of the tumor. Excluded represents re-
striction of more than 95% of all CD8+ T-cells in a
tumor to the periphery or interstitial stromal areas and
not actively invading nest or groups of neoplastic cells.
Mutational burden and RNAseq profiling
DNA and RNA was co-extracted from each sample and
processed for whole-exon DNAseq or RNAseq as previ-
ously described [17, 20]. Mutational burden and gene
expression were evaluated by targeted capture and se-
quencing of 409 cancer-related genes and amplicon se-
quencing of 394 immune transcripts, respectively, on
samples that met validated quality control (QC) thresh-
olds [17]. Somatic mutation calling was conducted using
Ion Torrent Suite software’s variant caller plugin (for de-
tailed information, please refer to Additional file 7). Mu-
tational burden cutoff was derived from a reference
population whereby the median MuB was 3.55 muta-
tions per megabase DNA. This value was used as a base-
line and a high MuB was defined as 2× this median
value (7.1).
Data analyses
Survival analysis was performed using a log-rank test on
5-year Kaplan-Meier survival curves for immune
markers including PD-L1 by IHC, pattern of CD8 ex-
pression by IHC, mutational burden by DNA-Seq
and targeted transcriptome profiling of 394 immune-
related genes by RNA-Seq (for detailed information,
please refer to Additional file 7). Hierarchical clustering
with Pearson’s correlation dissimilarity was performed
on 394 expression ranks for all samples. Overrepresenta-
tion test was performed on clusters to determine gene
enrichment, mutational landscape, other primary bio-
markers and clinical characteristics. A relative likelihood
of response to ICI, referred to as the response score (RS)
, was calculated based upon a weighted score of a gener-
alized linear model with additional input from CD8 ex-
pression and CD8+ T-cell infiltration pattern. The RS
was developed on 48 training patients and tested on a
validation set of 29 patients.
Results
PD-L1 immunohistochemistry and mutational burden
PD-L1 positivity (> 1% tumor cells with membranous
PD-L1 staining) [14, 15] was documented in 33% (98/
298) of all samples compatible with immunohistochemi-
cal evaluation. Amongst ICI-treated patients, PD-L1
positivity was associated with 55.6% ORR, while only 37.
9% of patients bearing PD-L1-negative melanoma
achieved an objective clinical response upon ICI-based
immunotherapy (Additional file 1: Table S3). ORR for
higher cut-off values for PD-L1 IHC showed similar re-
sults (Additional file 1: Table S7). A trend for improved
OS was observed amongst patients bearing PD-L1-
positive melanomas and undergoing treatment before
the introduction of ICIs (Fig. 1a; p = 0.081; Additional file
1: Table S2). However, the impact of PD-L1 positivity on
OS was much more considerable amongst patients
receiving ICI-based immunotherapy (Fig. 1b; p = 0.00036;
Additional file 1: Table S2), corroborating the predictive
value of PD-L1 expression levels measured by IHC and
stratified based on a 1% cut-off value.
A high mutational burden [3, 21], more than 7.1 som-
atic nonsynonymous mutations per million exonic bases,
could be documented in 21% (63/300) of all patients.
High mutational burden was associated with 33% ORR
amongst ICI-treated patients, while only 21% of patients
with a melanoma characterized by comparatively lower
mutational burden achieved an objective clinical re-
sponse following ICI-based immunotherapy (Additional file
1: Table S3). Mutational burden had no statistically signifi-
cant impact on OS, neither amongst historical controls
(Fig. 1c; p = 0.83; Additional file 1: Table S2), nor amongst
ICI-treated patients (Fig. 1d; p = 0.29; Additional file 1:
Table S2). Stratifying patients into 5, rather than 2, sub-
groups based on mutational burden failed to convey im-
proved predictive information (Additional file 3: Figure S2).
Thus, while high mutational burden was associated with a
slightly higher ORR amongst ICI-treated patients, the lack
of association with OS casts doubts on the predictive value
of mutational burden assessed as a standalone biomarker in
clinical practice.
Immune signature by unsupervised transcriptomics
Targeted transcriptomic analysis was performed on 394
immune transcripts including 11 housekeeping transcripts
[17], covering 45 different gene functions, for 300 meta-
static melanoma samples. Unsupervised hierarchical clus-
tering identified three major groups of samples
(Additional file 1: Table S2), with group 1 (n = 131; 44%)
being the most common, and groups 2 (n = 81; 27%) and
3 (n = 88; 29%) of comparable frequencies (Fig. 2a). An
analysis of gene functions at the individual gene level
across the groups allowed for an immunological delineation
of groups as: “inflamed” (group 1), “borderline” (group 2),
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and “immune desert” (group 3) (for detailed information,
please refer to Additional file 1: Table S3). IHC for PD-L1
expression levels unveiled a statistically significant associ-
ation (p = 1.63e-07) between PD-L1 positivity and the in-
flamed status (66/131; 50%), but PD-L1 positive tumors
were still quite common amongst both the borderline (26/
81; 32%) and immune desert (14/88; 20%) groups. Con-
versely, tumors with a high mutational burden were not
overrepresented (p = 0·98) in the inflamed group (25/131;
19%) as compared to the borderline (22/81; 27%) and im-
mune desert (16/88; 18%) groups. An overrepresentation
test (v.test) showed that the inflamed group was enriched
for tumors with a high number of CD8+ T cells, that the
immune desert group was enriched for tumors with a very
low number of CD8+ T cells, and that the borderline group
contained a mixture of tumors with high or low CD8+ T-
cell infiltration (for detailed information, please refer to
Additional file 1: Tables S4 and S5). Objective responses to
ICI-based immunotherapy, as assessed by RECIST v.1.1,
were much more common amongst inflamed tumors (20/
39; 51.28%), than amongst borderline (8/23; 34.78%) or im-
mune desert (5/16; 31.25%) tumors (for detailed informa-
tion, please refer to Additional file 1: Table S7). Altogether,
these findings suggest that borderline tumors may be clinic-
ally closer to immune desert tumors than to inflamed tu-
mors. In line with this notion, the inflamed status was
Fig. 1 Survival analysis of melanoma patients based on PD-L1 expression levels and mutational burden. a, b Overall survival upon stratification
based on PD-L1 positivity (tumor proportion score≥ 1% versus < 1%) for metastatic melanoma patients treated (a) prior to the introduction of ICIs
(historical controls; n = 94) and (b) ICI-treated melanoma patients (n = 137). c, d Overall survival upon stratification based on mutational burden
[high (≥ 7.1 mut/Mb) versus non-high] for metastatic melanoma patients treated (c) prior to the introduction of ICIs (historical controls; n = 94)
and (d) ICI-treated melanoma patients (n = 137). p-values are indicated
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associated with improved OS as compared with borderline
or immune desert status amongst ICI-treated patients,
but not amongst historical controls (Additional file 4:
Figure S3). Moreover, amongst inflamed tumors re-
ceiving ICI-based immunotherapy there was a trend
towards improved OS (Fig. 2b; p = 0.063; Additional
file 1: Table S2). The same did not hold true for bor-
derline (Fig. 2c; p = 0.33; Additional file 1: Table S2)
and immune desert (Fig. 2d; p = 0.88; Additional file 1:
Table S2) tumors.
Since unsupervised sample clustering closely correlated
with CD8+ T-cell quantification, a qualitative assessment
of CD8+ T-cell infiltration pattern was performed by IHC
(for detailed information, please refer to Additional file 7).
Samples were then classified into 3 patterns: non-
infiltrated, infiltrated, and excluded (Fig. 3a). Infiltration
(See figure on previous page.)
Fig. 2 Immunological landscape of melanoma and its association with multiple variables. a Unsupervised hierarchical clustering (rows = patients,
columns = genes) for 394 immune transcripts identified three major groups defined as “inflamed” (group 1), “borderline” (group 2), and “immune
desert” (group 3). CD8 (assessed by RNA-seq) and PD-L1 expression levels (assessed by immunohistochemistry), response to ICIs (as per RECIST
v.1.1), CD8 infiltration pattern (assessed by a trained pathologist, CM and APS), and mutational burden (assessed by whole-exon sequencing) are
depicted. b-d Overall survival for melanoma patients from the (b) inflamed (n = 131), (c) borderline (n = 81), and (d) immune desert (n = 88)
groups upon stratification based on treatment (historical controls versus ICI-based immunotherapy). p values are reported
Fig. 3 CD8+ T-cell infiltration pattern and clinical benefits from immune checkpoint inhibition. a CD8+ T-cell infiltration pattern was assessed by a
trained pathologist upon immunohistochemistry with a CD8-specific antibody. Representative images are depicted (scale bar = 500 μm or 1 mm).
b, c Overall survival upon stratification based on infiltration pattern (non-infiltrated, infiltrated, excluded) for metastatic melanoma patients treated
(b) prior to the introduction of ICIs (historical controls; n = 94) and (c) ICI-treated melanoma patients (n = 137). For all comparisons p > 0.05
Morrison et al. Journal for ImmunoTherapy of Cancer  (2018) 6:32 Page 7 of 12
pattern correlated with immune group, with infiltrated tu-
mors being mostly restricted to the inflamed group and
non-infiltrated tumors being more common in the im-
mune desert and borderline groups (Additional file 1:
Table S2). Interestingly though, excluded tumors were
evenly represented across all immune groups, represent-
ing about 10% of each. Infiltration pattern as assessed by
IHC for CD8+ T-cells failed to identify patient subsets
with an improved OS amongst historical controls (Fig. 3a;
p > 0.96 Additional file 1: Table S3). Conversely, ICI-
treated patients bearing infiltrated or excluded tumors be-
fore ICI treatment exhibited a superior OS as com-
pared to patients with non-infiltrated tumors (Fig. 3b&c;
p < 0.018 for all comparisons; Additional file 1: Table S2).
Relationship between tumor genomics and the immune
signature
Whole-exon sequencing of 409 cancer-related genes was
performed with the intent of evaluating potential associa-
tions between specific mutations with immune group (in-
flamed, borderline, and immune desert) (Additional file 5:
Figure S4; Additional file 1: Table S3). In particular, we har-
nessed the framework previously defined by the TCGA to
examine whether immunological status and/or clinical re-
sponse were associated with genetic driver subtypes: mu-
tant BRAF, mutant RAS, mutant NF1, and triple WT. [16]
From the 300 samples analyzed, a total of 264 samples
(88%) exhibited at least one genomic alteration, CDKN2A
loss (51%) being the most prevalent, followed by BRAF
(38%), RAS (16%) and NF1 (7.3%) mutations (Additional file
5: Figure S4). Consistent with previous reports, 46% of tu-
mors were classified as triple WT (Additional file 5: Figure
S4). Tumors bearing BRAF, RAS or NF1 mutations were
slightly overrepresented (60%; v.test = 1.71; p= 0.086) in the
immune desert group. The loss of CDKN2A was also signifi-
cantly associated (p= 0.00046) with the immune desert sta-
tus, but not with OS (p > 0.05). Apart from RAS mutations,
which were slightly associated with OS amongst historical
controls (p= 0.02) but not ICI-treated patients (p= 0.28), no
other statistically significant associations between genetic
drivers of the disease and OS could be documented (data
not shown).
Predicting response to checkpoint blockade beyond PD-
L1 levels and mutational burden
Transcriptomic data, mutational burden, and CD8+ T-cell
infiltration pattern were combined to derive an algorithmic
response score (RS) from a training set of 48 melanoma pa-
tients treated with ICI-based immunotherapy, and a valid-
ation cohort of 29 patients (Additional file 2: Figure S1 and
Additional file 7 for more details). ORR of the combined
training and test patients was 41.02% (8/78 CR, 24/78 PR,
16/78 SD, 29/78 PD) with the majority (68/78; 87.17%)
treated with single agent ICI-based immunotherapy.
Reference-normalized expression levels of 54 immune tran-
scripts [17] co-expressed with PD-L1 were selected from a
subset of 308 genes overexpressed in inflamed tumors (Wil-
coxon rank sum test p < 0.05) and combined with muta-
tional burden to derive a linear boundary of response
versus non-response via machine learning (AUC> 0·95;
Additional file 6: Figure S5). These values were then
weighted based on infiltration pattern (as assessed by a
trained pathologist) to obtain a score ranging from 0 to
100. RSs from the training and test cohorts were then com-
bined to build a relative likelihood of response analysis
upon linear regression fit (Fig. 4e; Additional file 1: Table
S6). Patients experiencing a CR showed significantly higher
RSs as compared to individual with SD (p = 0.0088) or PD
(p = 0.0057). Similarly, patients with PR had a significantly
higher RS than patients experiencing disease progression
(p = 0.0088; Fig. 4f). The distribution of objective response
rates from the training set versus response score groups
was evaluated for predicting response resulting in thresh-
old RS value of 50 (Additional file 1: Table S9). With this
threshold on a combined dataset, ICI-treated patients with
a RS ≥ 50 had a significantly improved OS and ORR of 82.
9% as compared to 23.8% for patients with RS < 50 (Fig. 4g;
p = 0.0012). Similar analyses on PD-L1 levels (Fig. 4a-b)
and mutational burden (Fig. 4c-d) were performed for
comparative purposes, showing no statistically significant
impact (p > 0.05). These analyses demonstrated that the RS
had a broad dynamic range for predicting response that
spanned from 30% to 100%. In comparison, the assessment
of PD-L1 levels by IHC and the evaluation of mutational
burden by whole-exon sequencing had dynamic ranges
spanning from 40 to 100% and 36–45%, respectively
(Additional file 1: Table S7).
Sensitivity, specificity, positive predictive value (PPV),
negative predictive value (NPV), and accuracy was evalu-
ated for all biomarkers, including RS, PD-L1 IHC, and
MuB for training, test, and combined datasets (Table 2).
For the combined datasets RS demonstrated higher sen-
sitivity (72.2%) compared to PD-L1 IHC (34.25%) and
tumor mutational burden (32.5%), but with similar spe-
cificity (Table 2). Accuracy, defined as the ratio of cor-
rect to total predictions, was likewise higher for RS (80.
52%) than for PD-L1 IHC (60.53%) and tumor muta-
tional burden (55.13%). From a clinical standpoint, RS
provides increased sensitivity and PPV while preserving
specificity and NPV when compared to PD-L1 IHC
and MuB, which is reflected in the improved accur-
acy. Similar results were observed for training and
test sets (Table 2).
Discussion
Our data suggest that predicting the likelihood that mel-
anoma patients will obtain durable clinical benefits from
ICI-based immunotherapy by assessing PD-L1 expression
Morrison et al. Journal for ImmunoTherapy of Cancer  (2018) 6:32 Page 8 of 12
Fig. 4 (See legend on next page.)
Morrison et al. Journal for ImmunoTherapy of Cancer  (2018) 6:32 Page 9 of 12
levels or mutational burden has two major challenges.
First, these biomarkers inform on key but limited compo-
nents of the immune cycle [22]. Second, these parameters
have only been used upon stratification towards binary
(positive/negative) decision making that lacks dynamic
range and suboptimal patient stratification for selection of
therapy. In this study, non-ICI treated patients (historical
controls) showed a limited survival advantage with posi-
tive PD-L1 expression (Fig. 1a), but no such effect was ob-
served with mutational burden (Fig. 1c). In other tumor
types, such as lung [23] and ovarian cancer [24] a high
mutational burden has a survival advantage in non-ICI
treated patients, but in both instances has been attributed
to DNA-repair deficiency primarily via BRCA1, BRCA2,
or POLE genes. In this study the mutational landscape of
both non-ICI and ICI-treated cohorts was primarily driven
by RAF/RAS mutations (Additional file 5: Figure S4) and
might explain the lack of impact of mutational burden on
survival in both instances.
Biomarkers that function as continuous variables, such
as the algorithmic RS presented in this study, provide
improved informational context in support of clinical
decision making. The performance of the RS in this
study is robust partially due to feature selection, which
was independent of the training and validation set and
initially derived from the unsupervised clustering of a
reference population of mixed tumor histologies. Indeed,
while the RS can be stratified based on a single cutoff
value (as displayed in our survival analysis), the extended
scope of inputs provides a much larger amount of infor-
mation inherent to the numerical value of the RS, mak-
ing it a suitable factor for improved decision making.
Thus, the RS seems to convey more predictive value
than the standalone assessment of PD-L1 levels or
mutational burden. As most patients used to derive the
RS in this study (87%) were treated with single agent
ICI-based immunotherapy, our data suggest that a mel-
anoma patient with a high RS should receive single
agent (rather than dual agent) ICI-based immunotherapy
in the clinical practice. Conversely, as most patients with
a low RS failed to respond to single agent ICI-based im-
munotherapy, dual agent ICI-based immunotherapy
would be the most appropriate choice for this group.
Intermediate RS values should be evaluated on a per pa-
tient basis in the context of other parameters such as
age, ECOG score, tolerance to side effects, etc.
While this work is not based upon a clinical trial it
was a multi-institutional study with several important
points. First, the features (genes) selected for the algo-
rithmic analysis were chosen from a prior study [17].
Second, the algorithmic analysis was developed from pa-
tient samples from a single institution (RPCCC) and
subsequently tested in a separate validation cohort from
eight different institutions to mimic a real-world clinical
scenario. Nonetheless, one of the major limitations of
the present study is that our final training (48 patients)
and test (29 patients) cohorts with RECIST v1.1 follow-
up were relatively small. In addition, we operated with
pooled data from patients receiving PD-1-targeting
agents (pembrolizumab or nivolumab), CTLA4-targeting
agents (ipilimumab), or both (nivolumab plus ipilimu-
mab). Additionally, due to limited sample size in the test
data set biomarker performance comparison for PD-L1
IHC, MuB, and RS was performed using the combined
training and test data set which could potentially result
in an over estimation of the accuracy of the comparative
biomarker results. Our current dataset does not allow
for the evaluation of these patients in a differential
(See figure on previous page.)
Fig. 4 Predictive performance of the RS as compared to PD-L1 expression levels and mutational burden. a Response rates for mutational burden
using a scale of very low, low, intermediate, high, and very high. While increasing response rates occur with an increase in mutational burden the
range of values from 36% to 45% is also limited for clinical use. b Box plot shows a pair-wise comparison of mutational burden for CR, PR, SD,
and PD. c Response rates for PD-L1 IHC using a tumor proportion score (TPS) with values of zero or negative, 1–4%, 5–10%, and > 10%. While in-
creasing response rates occur with an increase in TPS the range of values from 40% to 100% is limited for clinical use. d Box plot shows a pair-
wise comparison of PD-L1 IHC TPS for CR, PR, SD, and PD. e Objective response rates in groups of ICI-treated melanoma patients stratified by RS.
Linear regression supports a dynamic range from 30% to 100%. f Box plot shows a pair-wise comparison of RS values for CR, PR, SD, and PD. g
Overall survival upon stratification based on RS (≥ 50 versus < 50) for ICI-treated melanoma patients (n = 137), p value is indicated, for comprehen-
sive immune profiling using response score (RS) with a bin width of 10. Response rate shows a dynamic range of values from near zero to greater
than 95% with increasing RS. Survival curve for patients with a RS≥ 50 and < 50 shows an improved survival for the former (p = 0.0012)
Table 2 Prediction performance for studied biomarkers
Prediction Method Sensitivity Specificity PPV NPV Accuracy
Response Score (Training Dataset) 95.2% 74.1% 74.1% 95.2% 83.33%
Response Score (Test Dataset) 72.2% 81.8% 86.70% 64.30% 75.86%
Response Score (Combined) 84.6% 76.3% 78.60% 82.90% 80.52%
PD-L1 IHC (1% TPS) 34.2% 86.8% 72.20% 56.90% 60.53%
Mutational Burden 32.50% 78.90% 61.90% 52.60% 55.13%
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analysis with sufficient statistical power, therefore, a
multi-institutional prospective trial will be undertaken to
add confidence to our findings.
A potential confounding factor for this study was the
use of clone 28–8 for PD-L1 IHC and the relevance of
this stain for response to pembrolizumab as compared
to its complementary diagnostic status for nivolumab. In
this study the number of patients treated with pembroli-
zumab was greater than nivolumab and one could sup-
port that clone 22C3 would have been a better choice
for this set of patients for PD-L1 IHC. While this was
considered there is at least one multi-institutional study,
the Blueprint PD-L1 IHC Assay Comparison Project,
showing minimal differences between these two choices
[25], albeit in another tumor type. Another potential
confounding factor would be the role of driver muta-
tions in context of mutational burden estimation and re-
sponse to ICI. Prior meta-analyses in lung cancer have
shown decreased response to ICI in EGFR or ALK mu-
tant subgroups [26, 27], while BRAF mutations in mel-
anoma have shown the opposite effect [15]. It is
postulated that in some tumor types, such as lung can-
cer, these driver mutations do not contribute to “non-
self” immunogenicity in a manner comparable to nonsy-
nonymous passenger mutations [28]. In our estimation
of tumor mutational burden, which is designed to filter
‘hot-spot’ variants, the effect of driver mutations and
“non-self” immunogenicity therefore could not be the
result of the observed lack of association between muta-
tional burden and response.
Complex and multifactorial immune-biological mecha-
nisms may not be easily captured by a more simplistic
approach, such as one or a combination of single bio-
markers. The algorithmic RS as presented in this study
is a more complex approach that utilizes multiple factors
that allows for the evaluation of a wide range of im-
munosuppressive and activating mechanisms that are
not yet fully understood.
Conclusions
In summary, we demonstrated that an algorithmic ap-
proach for a comprehensive evaluation of the mutational
and immunological tumor landscape with a continuous
(rather than dichotomous) response score provides su-
perior informational context for predicting response to
ICIs in metastatic melanoma.
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